{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T12:40:15Z","timestamp":1741437615814,"version":"3.38.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T00:00:00Z","timestamp":1312934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12072-011-9293-8","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T14:46:51Z","timestamp":1312901211000},"page":"876-881","source":"Crossref","is-referenced-by-count":3,"title":["Prevention of post liver transplant HBV recurrence"],"prefix":"10.1007","volume":"5","author":[{"given":"Geoffrey W.","family":"McCaughan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,10]]},"reference":[{"key":"9293_CR1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I","volume":"61","author":"WC Maddrey","year":"2000","unstructured":"Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362\u2013326","journal-title":"J Med Virol"},{"key":"9293_CR2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","volume":"139","author":"HB El-Serag","year":"2003","unstructured":"El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817\u2013823","journal-title":"Ann Intern Med"},{"key":"9293_CR3","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1002\/lt.21637","volume":"14","author":"JR Lake","year":"2008","unstructured":"Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008;14:S23\u2013S26","journal-title":"Liver Transpl"},{"key":"9293_CR4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1600-6143.2010.03046.x","volume":"10","author":"B Degertekin","year":"1823","unstructured":"Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 1823;10:1823\u20131833","journal-title":"Am J Transplant"},{"key":"9293_CR5","doi-asserted-by":"crossref","unstructured":"Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; (1):6\u201312","DOI":"10.1016\/0270-9139(94)90045-0"},{"key":"9293_CR6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.21615","volume":"14","author":"F Zoulim","year":"2008","unstructured":"Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl 2008;14:S1\u2013S7","journal-title":"Liver Transpl"},{"key":"9293_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/jlts.2003.50005","volume":"9","author":"HW Hann","year":"2003","unstructured":"Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003;9:49\u201356","journal-title":"Liver Transpl"},{"key":"9293_CR8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","volume":"34","author":"FY Yao","year":"2001","unstructured":"Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411\u2013416","journal-title":"Hepatology"},{"key":"9293_CR9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.510310130","volume":"31","author":"JP Villeneuve","year":"2000","unstructured":"Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207\u2013210","journal-title":"Hepatology"},{"key":"9293_CR10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","volume":"123","author":"RJ Fontana","year":"2002","unstructured":"Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719\u2013727","journal-title":"Gastroenterology"},{"key":"9293_CR11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1002\/lt.21616","volume":"14","author":"AS Lok","year":"2008","unstructured":"Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008;14:S8\u2013S14","journal-title":"Liver Transpl"},{"key":"9293_CR12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521\u20131531","journal-title":"N Engl J Med;"},{"key":"9293_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","volume":"13","author":"E Schiff","year":"2007","unstructured":"Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349\u2013360","journal-title":"Liver Transpl."},{"key":"9293_CR14","first-page":"1419","volume":"38","author":"ER Schiff","year":"2003","unstructured":"Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419\u20131427","journal-title":"Hepatology"},{"key":"9293_CR15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","volume":"139","author":"G Woo","year":"2010","unstructured":"Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218\u20131229","journal-title":"Gastroenterology"},{"key":"9293_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","volume":"53","author":"YF Liaw","year":"2011","unstructured":"Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62\u201372","journal-title":"Hepatology"},{"key":"9293_CR17","doi-asserted-by":"crossref","unstructured":"Garg H, Sarin SK, Kumar M, et al. (2011) Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology","DOI":"10.1002\/hep.24109"},{"key":"9293_CR18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2009","unstructured":"Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2009;52:176\u2013182","journal-title":"J Hepatol"},{"issue":"6","key":"9293_CR19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","volume":"50","author":"CM Lange","year":"2009","unstructured":"Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50(6):2001\u20132016","journal-title":"Hepatology"},{"issue":"2","key":"9293_CR20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2010.06.043","volume":"54","author":"VW Wong","year":"2011","unstructured":"Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011;54(2):236\u2013242","journal-title":"J Hepatol"},{"key":"9293_CR21","doi-asserted-by":"crossref","unstructured":"Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. (2011) Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. Hepatology","DOI":"10.1002\/hep.24361"},{"key":"9293_CR22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(91)92515-4","volume":"337","author":"D Samuel","year":"1991","unstructured":"Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813\u2013815","journal-title":"Lancet"},{"key":"9293_CR23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","volume":"329","author":"D Samuel","year":"1993","unstructured":"Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842\u20131847","journal-title":"N Engl J Med"},{"key":"9293_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.1840210104","volume":"199521","author":"PW Angus","year":"1995","unstructured":"Angus PW, Locarnini SA, McCaughan GW, et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995;21:14\u201318","journal-title":"Hepatology"},{"key":"9293_CR25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.510240610","volume":"24","author":"JS McMillan","year":"1996","unstructured":"McMillan JS, Bowden DS, Angus PW, et al. Mutations in the hepatitis B virus precore\/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996;24:1371\u20131378","journal-title":"Hepatology"},{"key":"9293_CR26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0168-8278(99)80204-9","volume":"30","author":"D Mutimer","year":"1999","unstructured":"Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999;30:715\u2013721","journal-title":"J Hepatol"},{"key":"9293_CR27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)04444-3","volume":"348","author":"L Grellier","year":"1996","unstructured":"Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212\u20131215","journal-title":"Lancet"},{"key":"9293_CR28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","volume":"33","author":"RP Perrillo","year":"2001","unstructured":"Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424\u2013432","journal-title":"Hepatology"},{"key":"9293_CR29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2003.50035","volume":"37","author":"CM Lo","year":"2003","unstructured":"Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003;37:36\u201343","journal-title":"Hepatology"},{"key":"9293_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/lt.20887","volume":"13","author":"Y Luo","year":"2007","unstructured":"Luo Y, Lo CM, Cheung CK, et al. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl 2007;13:71\u201379","journal-title":"Liver Transpl"},{"key":"9293_CR31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.510280241","volume":"28","author":"JS Markowitz","year":"1998","unstructured":"Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585\u2013589","journal-title":"Hepatology"},{"key":"9293_CR32","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0168-8278(01)00080-0","volume":"34","author":"A Marzano","year":"2001","unstructured":"Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903\u2013910","journal-title":"J Hepatol"},{"issue":"6","key":"9293_CR33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/jlts.2000.18702","volume":"6","author":"SH Han","year":"2000","unstructured":"Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6(6):741\u2013748","journal-title":"Liver Transpl"},{"key":"9293_CR34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jlts.2000.8310","volume":"6","author":"PW Angus","year":"2000","unstructured":"Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429\u2013433","journal-title":"Liver Transpl"},{"key":"9293_CR35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","volume":"132","author":"EJ Gane","year":"2007","unstructured":"Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931\u2013937","journal-title":"Gastroenterology"},{"key":"9293_CR36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.transproceed.2005.12.063","volume":"38","author":"S Karademir","year":"2006","unstructured":"Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006;38:579\u2013583","journal-title":"Transplant Proc"},{"key":"9293_CR37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.tp.0000246310.75638.86","volume":"83","author":"A Takaki","year":"2007","unstructured":"Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007;83:231\u2013233","journal-title":"Transplantation"},{"key":"9293_CR38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1399-0012.2005.00467.x","volume":"20","author":"DS Nath","year":"2006","unstructured":"Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006;20:206\u2013210","journal-title":"Clin Transplant"},{"key":"9293_CR39","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","volume":"48","author":"PW Angus","year":"2008","unstructured":"Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460\u20131466","journal-title":"Hepatology"},{"key":"9293_CR40","first-page":"1600","volume":"7","author":"S Saab","year":"2011","unstructured":"Saab S, Desai S, Tsaoi D, et al. Posttransplantation Hepatitis B Prophylaxis with Combination Oral Nucleoside and Nucleotide Analog Therapy. Am J Transplant 2011;7:1600\u20136143","journal-title":"Am J Transplant"},{"key":"9293_CR41","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/lt.22169","volume":"16","author":"CK Cheung","year":"2010","unstructured":"Cheung CK, Lo CM, Man K, et al. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl 2010;16:1314\u20131323","journal-title":"Liver Transpl"},{"issue":"1","key":"9293_CR42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/jhep.2002.30278","volume":"35","author":"M Angelico","year":"2002","unstructured":"Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35(1):176\u2013181","journal-title":"Hepatology"},{"key":"9293_CR43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840380407","volume":"38","author":"U Bienzle","year":"2003","unstructured":"Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38:811\u2013819","journal-title":"Hepatology"},{"key":"9293_CR44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.03.013","volume":"43","author":"CM Lo","year":"2005","unstructured":"Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005;43:283\u2013287","journal-title":"J Hepatol"},{"key":"9293_CR45","first-page":"38","volume":"5","author":"M Wadhawan","year":"2011","unstructured":"Wadhawan M, Gupta S, Vij V, et al. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immunoglobulin (HBIG). Hepatol Int 2011;5:38","journal-title":"Hepatol Int"},{"key":"9293_CR46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/lt.21998","volume":"16","author":"S Saab","year":"2010","unstructured":"Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl 2010;16:300\u2013307","journal-title":"Liver Transpl"},{"key":"9293_CR47","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","volume":"52","author":"E Cholongitas","year":"2010","unstructured":"Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010;52:272\u2013279","journal-title":"J Hepatol"},{"key":"9293_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1478-3231.2010.02320.x","volume":"31","author":"S Pascarella","year":"2010","unstructured":"Pascarella S, Negro F, Hepatitis D. virus: an update. Liver Int 2010;31:7\u201321","journal-title":"Liver Int"},{"key":"9293_CR49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322\u2013331","journal-title":"N Engl J Med"},{"key":"9293_CR50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.1840210211","volume":"21","author":"D Samuel","year":"1995","unstructured":"Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995;21:333\u2013339","journal-title":"Hepatology"},{"key":"9293_CR51","doi-asserted-by":"crossref","unstructured":"Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008;134:1890\u20131899 (quiz 2155)","DOI":"10.1053\/j.gastro.2008.02.064"},{"key":"9293_CR52","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/lt.21882","volume":"15","author":"S Saab","year":"2009","unstructured":"Saab S, Yeganeh M, Nguyen K, et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009;15:1525\u20131534","journal-title":"Liver Transpl"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-011-9293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-011-9293-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-011-9293-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T12:21:35Z","timestamp":1741436495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-011-9293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9293"],"URL":"https:\/\/doi.org\/10.1007\/s12072-011-9293-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2011,8,10]]}}}